Lidocaine intravesicular - TARIS Biomedical

Drug Profile

Lidocaine intravesicular - TARIS Biomedical

Alternative Names: LiRIS®

Latest Information Update: 26 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TARIS Biomedical
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Interstitial cystitis

Most Recent Events

  • 06 May 2016 Efficacy and adverse event data from a phase Ib trial in Interstitial cystitis presented at the Annual Meeting of the American Urological Association (AUA-2016)
  • 02 Sep 2015 Phase-II development for Interstitial cystitis is ongoing in USA and Canada
  • 01 May 2015 Allergan initiates enrolment in a phase II trial in Interstitial cystitis in USA (NCT02411110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top